Critical Care Continuing Medical Education
Be part of the knowledge.™Episodes 1-15 of 19
Comparing In-hospital Mortality With Andexanet Alfa Versus 4-Factor Prothrombin Complex Concentrate
MinuteCE®Comparing In-hospital Mortality With Andexanet Alfa Versus 4-Factor Prothrombin Complex Concentrate
Life-Threatening Bleeding in the Anticoagulated Patient: Real World Evidence
MinuteCE®Life-Threatening Bleeding in the Anticoagulated Patient: Real World Evidence
Andexanet Alfa Is Associated With Lower In-Hospital Mortality Compared to 4-Factor Prothrombin Complex Concentrate in Patients With Factor Xa Inhibitor–Related Major Bleeding
MinuteCE®Andexanet Alfa Is Associated With Lower In-Hospital Mortality Compared to 4-Factor Prothrombin Complex Concentrate in Patients With Factor Xa Inhibitor–Related Major Bleeding
Case Presentation: Management of a Patient With Vitamin K Antagonist-Associated Intracranial Hemorrhage (ICH)
MinuteCE®Case Presentation: Management of a Patient With Vitamin K Antagonist-Associated Intracranial Hemorrhage (ICH)
Reversal of Factor Xa Inhibitor ICH: ANNEXA-4, ANNEXA-I and Real-World Evidence
MinuteCE®Reversal of Factor Xa Inhibitor ICH: ANNEXA-4, ANNEXA-I and Real-World Evidence
Case Presentation: Management of a Patient With Factor Xa-Associated ICH Using Specific Reversal Therapy
MinuteCE®Case Presentation: Management of a Patient With Factor Xa-Associated ICH Using Specific Reversal Therapy
Development of a Care Pathway Using Specific Reversal Agents for Anticoagulated Patients With ICH
MinuteCE®Development of a Care Pathway Using Specific Reversal Agents for Anticoagulated Patients With ICH
Reinforcement of Principles, Overcoming Treatment Barriers, and Improving Time to Treatment for ICH
MinuteCE®Reinforcement of Principles, Overcoming Treatment Barriers, and Improving Time to Treatment for ICH
Repletion Management for Vitamin K Antagonist Anticoagulation
MinuteCE®Repletion Management for Vitamin K Antagonist Anticoagulation
Specific Reversal Therapy for Factor Xa and Factor IIa Inhibitor-Associated ICH Life-Threatening Bleeding
MinuteCE®Specific Reversal Therapy for Factor Xa and Factor IIa Inhibitor-Associated ICH Life-Threatening Bleeding
Case Presentation: Management of ICH in the Anticoagulated Patient Using Specific Reversal Therapy: Importance of Timing
MinuteCE®Case Presentation: Management of ICH in the Anticoagulated Patient Using Specific Reversal Therapy: Importance of Timing
Repletion or Reversal? Optimizing Specific Therapy for Direct Oral Anticoagulant (DOAC)-Related Life-Threatening Bleeding Using Real-World Experience
MinuteCE®Repletion or Reversal? Optimizing Specific Therapy for Direct Oral Anticoagulant (DOAC)-Related Life-Threatening Bleeding Using Real-World Experience
Hematoma Expansion and Clinical Outcomes Comparison in ICH: Clinical Trial Results Versus Real World Care
MinuteCE®Hematoma Expansion and Clinical Outcomes Comparison in ICH: Clinical Trial Results Versus Real World Care
